Inclusion Criteria:

- Written informed consent obtained prior to study enrollment.

- Male or female aged six (6) months or older.

- Subject is currently exhibiting two or more symptoms associated with COVID-19,
influenza or RSV (such as, but not limited to, fever, chills, cough, shortness of
breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat,
congestion or runny nose, nausea or vomiting or diarrhea and must present within six
(6) days of symptom onset). Subject must still be exhibiting symptoms on the day of
sample collection.

Exclusion Criteria:

- Subject who is 18 years of age (or the state's legal age of majority) or older and
does not understand or is not able and willing to sign the study informed consent.

- Subject has had seasonal influenza and/or the SARS-CoV-2 and/or the RSV vaccine
within the past 5 days.

- Subject is not able to tolerate sample collection, or is not willing to contribute
the required swab samples for testing or complete the study procedures.

- Subject is currently undergoing antiviral treatment such as baloxavir marboxil
(trade name Xofluza®), oseltamivir (Tamiflu®), zanamivir (Relenza®), or peramivir
(Rapivab®).

- Subjects currently undergoing treatment and/or within the past thirty (30) days with
prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may
include but is not limited to Remdesivir (Veklury), Paxlovid, molnupiravir or
receiving convalescent plasma therapy for SARS-CoV-2.

- Subjects who have taken Evusheld (tixagevimab/cilgavimab) within the last 90 days.

- Subjects who have had a nasal wash or aspirate as part of their standard of care
treatment on day of study visit prior to the study sample collection.

- Subjects who have had recent craniofacial injury or surgery, including to correct
deviation of the nasal septum, within the previous six (6) months.